Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Trial Profile

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 According to a Mesoblast media release, this trial is funded by in a United States National Institutes of Health (NIH).
    • 27 Feb 2017 According to a Mesoblast media release, results of this trial will be used to guide the discussions with the United States Food and Drug Administration (FDA) in line with the 21st Century Cures Act for potential accelerated approval pathways for MPC-150-IM.
    • 27 Feb 2017 According to a Mesoblast media release, an enrollment of this trial is expected to be completed during 1H 2017 with a data read-out planned in 2H 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top